Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fate Therapeutics (FATE) has shared an announcement.
Fate Therapeutics, Inc. has announced the appointment of J. Scott Wolchko as the new Chief Financial Officer and principal financial and accounting officer, following the resignation of Edward J. Dulac III. Wolchko, already serving as President and CEO, has previously held the CFO position at the company until August 2020. His biographical and compensation information is detailed in the Proxy Statement filed with the Securities and Exchange Commission. Additionally, all proposals at the Annual Meeting, including the election of directors, ratification of Ernst & Young LLP as the accounting firm, and approval of executive compensation, were passed by the stockholders.
See more data about FATE stock on TipRanks’ Stock Analysis page.